



## Antimicrobial Resistance during the COVID-19 Outbreak

Guest Editors:

**Dr. Timothy Rawson**

Faculty of Medicine, Department  
of Infectious Disease, Imperial  
College London, London, UK

timothy.rawson07@  
imperial.ac.uk

**Dr. Luke S. P. Moore**

Faculty of Medicine, Department  
of Infectious Disease, Imperial  
College London, London, UK

l.moore@imperial.ac.uk

**Prof. Alison Holmes**

Faculty of Medicine, Department  
of Infectious Disease, Imperial  
College London, London, UK

alison.holmes@imperial.ac.uk

Deadline for manuscript  
submissions:

**1 October 2021**

### Message from the Guest Editors

Dear Colleagues,

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent pandemic has placed an immense strain on healthcare systems worldwide. The challenges posed by the diagnosis and management of coronavirus disease 2019 (COVID-19) together with concerns regarding associated bacterial and fungal infection have promoted the extensive use of antimicrobials in acute care. In contrast, in the community, we have observed a reduction of antimicrobial use. The impact that the COVID-19 pandemic will have on antimicrobial resistance in the long term remains unknown.

We are pleased to invite you to contribute to this Special Issue of *Antibiotics*. The aim of this Special Issue is to provide insights into the impact of COVID-19 on antimicrobial use and antimicrobial resistance. We also aim to highlight and discuss specific interventions that have been developed to address inappropriate antimicrobial use and antimicrobial resistance during the pandemic.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:**— free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases.

**Journal Rank:** JCR - Q2 (*Infectious Diseases*) / CiteScore - Q2 (*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

---

*Antibiotics*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
@antibioticsmdpi